Effect of allopurinol on smoking.
Noemí
N
Esparza-Martín
Santiago
S
Suria-González
César
C
García-Cantón
Ana
A
Ramírez-Puga
Rita
R
Guerra-Rodríguez
M Dolores
MD
Checa-Andrés
D000109:Acetylcholine / Q000737:chemistry; D000493:Allopurinol / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D001552:Benzazepines / Q000737:chemistry; D001923:Brain Chemistry / Q000187:drug effects; D016642:Bupropion / Q000737:chemistry; D015984:Causality; D015897:Comorbidity; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000453:epidemiology / Q000523:psychology; D006801:Humans; D019271:Hypoxanthine / Q000378:metabolism; D015394:Molecular Structure; D009538:Nicotine / Q000737:chemistry; D018722:Nicotinic Agonists / Q000737:chemistry; D011810:Quinoxalines / Q000737:chemistry; D012907:Smoking / Q000453:epidemiology*; D016540:Smoking Cessation / Q000523:psychology; D013329:Structure-Activity Relationship; D000068580:Varenicline; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors
D001552:Benzazepines; D018722:Nicotinic Agonists; D011810:Quinoxalines; D016642:Bupropion; D019271:Hypoxanthine; D000493:Allopurinol; D009538:Nicotine; D014969:Xanthine Oxidase; D000109:Acetylcholine; D000068580:Varenicline